psalexa
logo

Proteasome Inhibitors Therapeutics Pipeline, 2017

Proteasome Inhibitors Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: October 2017
Report Code: LS11327
Available Format:
Pages: 89

Overview

Proteasome inhibitors are the drugs that block the proteasomes, a cellular component that breakdown proteins. The proteasome inhibitors are being studied in the treatment of multiple myeloma, cancer, inflammatory disorders, and autoimmune disorders. A breakthrough multiple myeloma treatment received approval 2003 for, Bortezomib, the first proteasome inhibitor, which is a reversible boronic acid inhibitor of the chymotrypsin-like activity of proteasome. Other proteasome inhibitors such as, ixazomib and delanzomib, are in the late stage of clinical development and are reversible boronic acid proteasome inhibitors.

 

PROTEASOME INHIBITORS THERAPEUTICS CANDIDATES UNDER DEVELOPMENT (2017)
PROTEASOME INHIBITORS THERAPEUTICS
 

There are many pharmaceutical companies that are using different technologies for better development of drug candidates. These technologies can be helpful in the development of drugs as combination therapies or as single agent therapies. They also allow the development of specific targeted therapies with better drug delivery. For instance, in Cellivery’s Technology Platform, protein transduction exploits the ability of specific basic-, amphipathic- and hydrophobic-cell penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Cellivery Therapeutics, Inc has developed hydrophobic cell penetrating peptide, named macromolecule transduction domains (MTD) to deliver biologically active peptides and proteins into a variety of cells and tissues.

Pipeline Analysis

As of October 2017, the proteasome inhibitors pipeline comprised of approximately 20 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs as proteasome inhibitors include Triphase Accelerator Corporation, Cantex Pharmaceuticals, Inc., Accuitis, Inc. and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry